title: Xenotropic MLV envelope proteins induce tumor cells to secrete factors that promote the formation of immature blood vessels.
abstract: BACKGROUND
  Xenotropic Murine leukemia virus-Related Virus (XMRV) is a γ-retrovirus initially reported to be present within familial human prostate tumors and the blood of patients with chronic fatigue syndrome. Subsequent studies however were unable to replicate these findings, and there is now compelling evidence that the virus evolved through rare retroviral recombination events in human tumor cell lines established through murine xenograft experiments. There is also no direct evidence that XMRV infection has any functional effects that contribute to tumor pathogenesis.
  
  
  RESULTS
  Herein we describe an additional xenotropic MLV, "B4rv", found in a cell line derived from xenograft experiments with the human prostate cancer LNCaP cell line. When injected subcutaneously in nude mice, LNCaP cells infected with XMRV or B4rv formed larger tumors that were highly hemorrhagic and displayed poor pericyte/smooth muscle cell (SMC) investment, markers of increased metastatic potential. Conditioned media derived from XMRV- or B4rv-infected LNCaPs, but not an amphotropic MLV control virus infected LNCaPs, profoundly decreased expression of marker genes in cultured SMC, consistent with inhibition of SMC differentiation/maturation. Similar effects were seen with a chimeric virus of the amphotropic MLV control virus containing the XMRV env gene, but not with an XMRV chimeric virus containing the amphotropic MLV env gene. UV-inactivated XMRV and pseudovirions that were pseudotyped with XMRV envelope protein also produce conditioned media that down-regulated SMC marker gene expression in vitro.
  
  
  CONCLUSIONS
  Together these results indicate that xenotropic MLV envelope proteins are sufficient to induce the production of factors by tumor cells that suppress vascular SMC differentiation, providing evidence for a novel mechanism by which xenotropic MLVs might alter tumor pathogenesis by disrupting tumor vascular maturation. Although it is highly unlikely that either XMRV or B4Rv themselves infect humans and are pathogenic, the results suggest that xenograft approaches commonly used in the study of human cancer promote the evolution of novel retroviruses with pathogenic properties.
authors.affiliation: Robert M, Berne Cardiovascular Research Center, University of Virginia, School of Medicine Charlottesville, Charlottesville, VA 22908, USA.
authors.forename: Meera
authors.initials: M
authors.lastname: Murgai
authors.forename: James
authors.initials: J
authors.lastname: Thomas
authors.forename: Olga
authors.initials: O
authors.lastname: Cherepanova
authors.forename: Krista
authors.initials: K
authors.lastname: Delviks-Frankenberry
authors.forename: Paul
authors.initials: P
authors.lastname: Deeble
authors.forename: Vinay K
authors.initials: VK
authors.lastname: Pathak
authors.forename: David
authors.initials: D
authors.lastname: Rekosh
authors.forename: Gary
authors.initials: G
authors.lastname: Owens
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D015686:Gene Products, env / Q000378:metabolism*; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009389:Neovascularization, Pathologic; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000821:virology*; D058008:Xenotropic murine leukemia virus-related virus / Q000472:pathogenicity*
chemical_list: D015686:Gene Products, env
references.citation: Prostate. 2012 Jun 1;72(8):886-97
references.pmid: 21932423
references.citation: Rev Med Virol. 2008 Nov-Dec;18(6):387-405
references.pmid: 18729235
references.citation: Virol J. 2011 Sep 06;8:423
references.pmid: 21896167
references.citation: Retrovirology. 2009 Oct 16;6:92
references.pmid: 19835577
references.citation: Science. 2011 Jul 1;333(6038):97-101
references.pmid: 21628392
references.citation: Science. 1970 Oct 16;170(3955):326-7
references.pmid: 4318971
references.citation: PLoS One. 2011 May 04;6(5):e19065
references.pmid: 21573232
references.citation: Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2)
references.pmid: 10881018
references.citation: Am J Hum Genet. 2002 Oct;71(4):981-4
references.pmid: 12145743
references.citation: Viruses. 2010 Dec;2(12):2618-48
references.pmid: 21994634
references.citation: Xenotransplantation. 2012 Mar-Apr;19(2):72-81
references.pmid: 22497509
references.citation: BMJ. 2010 Feb 25;340:c1018
references.pmid: 20185493
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Virology. 2010 Mar 30;399(1):23-30
references.pmid: 20110097
references.citation: J Virol. 2010 Feb;84(4):1874-80
references.pmid: 20007266
references.citation: Nat Genet. 2003 Jan;33(1):49-54
references.pmid: 12469122
references.citation: J Gen Virol. 2012 May;93(Pt 5):915-924
references.pmid: 22357751
references.citation: PLoS Pathog. 2006 Mar;2(3):e25
references.pmid: 16609730
references.citation: Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):381-8
references.pmid: 17681844
references.citation: PLoS One. 2010 Jul 23;5(7):e11738
references.pmid: 20668529
references.citation: PLoS One. 2012;7(7):e42321
references.pmid: 22848758
references.citation: J Virol. 1996 May;70(5):3142-52
references.pmid: 8627794
references.citation: Retrovirology. 2010 Dec 20;7:109
references.pmid: 21171973
references.citation: Cancer Res. 2004 Jun 1;64(11):3731-6
references.pmid: 15172975
references.citation: Neuro Oncol. 2010 Mar;12(3):233-42
references.pmid: 20167811
references.citation: Science. 2011 Jul 1;333(6038):94-7
references.pmid: 21628393
references.citation: Circ Res. 1988 Apr;62(4):749-56
references.pmid: 3280155
references.citation: Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006486
references.pmid: 22393532
references.citation: Science. 2009 Oct 23;326(5952):585-9
references.pmid: 19815723
references.citation: J Microsc. 2006 Dec;224(Pt 3):213-32
references.pmid: 17210054
references.citation: Retrovirology. 2009 Oct 07;6:87
references.pmid: 19811656
references.citation: PLoS One. 2012;7(5):e36072
references.pmid: 22615748
references.citation: J Virol. 2012 Feb;86(3):1661-9
references.pmid: 22090134
references.citation: J Virol. 2008 Oct;82(20):9964-77
references.pmid: 18684813
references.citation: J Clin Invest. 2006 Mar;116(3):642-51
references.pmid: 16470244